



Stroke prevention in atrial fibrillation: Late-breaking insights from the RE-LY® trial

Boehringer Ingelheim Satellite Symposium

Monday 31 August; 18:30–20:00
(Dinner reception from 18:10)
Barcelona, Zone 2

Please join us for lively discussions on the latest
advances in stroke prevention in atrial fibrillation

Co-chairs: Salim Yusuf and Gregory Y H Lip

18:30 Chairman's introduction

Gregory Y H Lip, University Department of Medicine,
City Hospital, Birmingham, UK

18:35 Direct thrombin inhibition: a new approach to anticoagulation

Jeff Weitz, McMaster University, Hamilton, Canada

18:45 RE-LY® trial design and demographics

Michael D Ezekowitz, Lankenau Institute for Medical Research,
Wynnewood, USA

18:55 Efficacy of dabigatran etexilate for prevention of stroke in atrial fibrillation

Lars Wallentin, University Hospital, Uppsala, Sweden

19:10 Safety of dabigatran etexilate for prevention of stroke in atrial fibrillation

Stuart Connolly, McMaster University, Hamilton, Canada

19:20 Impact of RE-LY® and its relevance to current clinical practice

Jonathan Halperin, Mount Sinai Medical Center, New York, USA

19:35 Panel discussion

All faculty and audience

19:55 Key learning points and close of meeting

Salim Yusuf, McMaster University, Hamilton, Canada